FATE Earnings & Financial Statements
Fate Therapeutics, Inc.
$1.94
-$0.06(-3.00%)
40
Overall
60
Value
20
Tech
42
Quality
Market Cap
$232.45M
Volume
1.67M
52W Range
$0.95 - $3.23
Target Price
$5.74
FATE earnings and financial statements: Fate Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
FATE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $6.65M | $13.63M | $63.53M | $96.30M | $55.85M |
| Operating income | -$147.70M | -$210.28M | -$190.51M | -$308.39M | -$216.99M |
| EBITDA | -$123.42M | -$167.26M | -$147.48M | -$294.63M | -$211.14M |
| Net income | -$136.31M | -$186.26M | -$160.93M | -$281.72M | -$212.15M |
| EPS (diluted) | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $318.94M | $440.69M | $506.22M | $705.56M | $921.46M |
| Total liabilities | $100.91M | $116.37M | $137.80M | $221.62M | $242.62M |
| Shareholders’ equity | $207.18M | $318.73M | $368.42M | $483.94M | $678.84M |
| Cash and equivalents | $46.63M | $36.06M | $41.87M | $61.33M | $133.58M |
| Long-term debt | $73.29M | $77.85M | $97.36M | $103.71M | $109.24M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$106.08M | -$122.87M | -$132.26M | -$248.21M | -$162.87M |
| Capital expenditure | -$5.59M | -$730.0K | -$6.15M | -$35.57M | -$50.70M |
| Free cash flow | -$112.04M | -$123.60M | -$138.42M | -$283.77M | -$213.57M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FATE | $1.94 | -3.0% | 1.67M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |